Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Vandercam

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Molecular Diagnostics : JMD|October 4, 2008
Amplification-based DNA analysis in the diagnosis of prosthetic joint infectionBernard Vandercam, Sabine Jeumont, Olivier Cornu, et al.
Clinical Biochemistry|January 9, 2016
Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interactionLeïla Belkhir, Morgane De Laveleye, Bernard Vandercam, et al.
AIDS (London, England)|April 15, 2020
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patientsRakan Nasreddine, Eric Florence, Bernard Vandercam, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 21, 2019
Mortality in patients with high risk Staphylococcus aureus bacteremia undergoing or not PET-CT: A single center experienceHalil Yildiz, Gregory Reychler, Hector Rodriguez-Villalobos, et al.
Acta Clinica Belgica|April 7, 2018
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patientsStéphane De Wit, Eric Florence, Linos Vandekerckhove, et al.
BMC Infectious Diseases|January 14, 2011
Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007Bakhao Ndiaye, Julia Salleron, Anne Vincent, et al.
The Journal of Infectious Diseases|March 4, 2025
Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic StudyJulien De Greef, Jean Cyr Yombi, Anne Vincent, et al.
Acta Clinica Belgica|May 3, 2018
Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients<sup></sup>Stéphane De Wit, Eric Florence, Linos Vandekerkhove, et al.
Scientific Reports|July 1, 2025
Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional studyJulien De Greef, Khoi Nguyen Nguyen, Matthias Van Hul, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 1, 2005
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudyFrank van Leth, Casper B Huisamen, Roberto Badaro, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Molecular Diagnostics : JMD|October 4, 2008
Amplification-based DNA analysis in the diagnosis of prosthetic joint infectionBernard Vandercam, Sabine Jeumont, Olivier Cornu, et al.
Clinical Biochemistry|January 9, 2016
Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interactionLeïla Belkhir, Morgane De Laveleye, Bernard Vandercam, et al.
AIDS (London, England)|April 15, 2020
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patientsRakan Nasreddine, Eric Florence, Bernard Vandercam, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 21, 2019
Mortality in patients with high risk Staphylococcus aureus bacteremia undergoing or not PET-CT: A single center experienceHalil Yildiz, Gregory Reychler, Hector Rodriguez-Villalobos, et al.
Acta Clinica Belgica|April 7, 2018
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patientsStéphane De Wit, Eric Florence, Linos Vandekerckhove, et al.
BMC Infectious Diseases|January 14, 2011
Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007Bakhao Ndiaye, Julia Salleron, Anne Vincent, et al.
The Journal of Infectious Diseases|March 4, 2025
Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic StudyJulien De Greef, Jean Cyr Yombi, Anne Vincent, et al.
Acta Clinica Belgica|May 3, 2018
Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients<sup></sup>Stéphane De Wit, Eric Florence, Linos Vandekerkhove, et al.
Scientific Reports|July 1, 2025
Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional studyJulien De Greef, Khoi Nguyen Nguyen, Matthias Van Hul, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 1, 2005
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudyFrank van Leth, Casper B Huisamen, Roberto Badaro, et al.
Pageof 4